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We investigated the ameliorative effects and potential mechanisms of tannic acid (TA) in carbon tetra-
chloride (CCl4)-intoxicated mice and hepatic stellate cells (HSCs). Liver ﬁbrosis was observed in CCl4
(800 ml/kg)-induced mice, and high viability was observed in CCl4 (10 mM)-intoxicated HSCs. Pre-
treatment of mice with TA (25 or 50 g/kg/day) signiﬁcantly ameliorated hepatic morphology and coef-
ﬁcient values and reduced the activities of aspartate aminotransferase (AST) and alanine aminotrans-
ferase (ALT), the concentrations of malondialdehyde (MDA) and serum levels of endothelin-1 (ET-1). In
addition, TA increased the activities of superoxide dismutase (SOD), catalase (CAT), glutathione peroxi-
dase (GSH-Px), and endothelial nitric oxide synthase (eNOS) and the serum level of NO. Moreover, TA
reduced the expression of angiotensin II receptor-1 (ATR-1), interleukin-1b (IL-1b), tumor necrosis factor-
a (TNF-a), transforming growth factor-b (TGF-b), caspase-3, c-fos, c-jun, the ratio of Bax/bcl-2, tissue
inhibitor of metalloproteinase-1 (TIMP-1) and TA increased matrix metal proteinase-9 (MMP-9), matrix
metalloproteinase-1 (MMP-1). Furthermore, TA (0.01 mM, 0.1 mM or 1 mM) decreased the TIMP-1/MMP-1
ratio and reduced the viability of HSCs. These results indicated that TA exerts signiﬁcant liver-protective
effects in mice with CCl4-induced liver ﬁbrosis. The potential mechanism may rely on the inhibition of
collagen accumulation, oxidative stress, inﬂammation and apoptosis.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
A continuous ﬁbrogenic stimulus, such as the physiological
response of chronically activated wound healing, can lead to he-
patic ﬁbrosis and even cirrhosis (1, 2). Hepatic ﬁbrosis is charac-
terized by reversible scarring and the massive deposition of
extracellular matrix (ECM) in the liver (3). During ﬁbrogenesis,The Fourth Hospital of Hebei
050011, Hebei, China. Tel./
rmacological Society.
. Production and hosting by ElseHSCs are activated and excessive ECM components, such as hyal-
uronic acid, ﬁbronectins and collagens, accumulate (4). In addition,
activated HSCs exhibit a strong proliferative activity by expressing
excessive collagen I and a-smooth muscle actin and secreting
chemotactic cytokines and pro-inﬂammatory cytokines (5).
Inﬂammation plays an important role in the stimulation of HSCs
and hepatic ﬁbrosis (6). These liver disorders are associated with a
signiﬁcant mortality risk; over 100 million people are affected by
this disease worldwide (7, 8), and cirrhosis is the leading cause of
liver disease-related mortality worldwide. Therefore, it is vital to
develop therapeutic strategies for inhibiting liver ﬁbrosis.
Tannic acid (TA), which is a component of traditional Chinese
medicines (TCMs) (Fig. 1D), widely exists in cereals, legumes, fruits,vier B.V. This is an open access article under the CC BY-NC-ND license (http://
X. Chu et al. / Journal of Pharmacological Sciences 130 (2016) 15e2316herbs, green tea and red wine (4). This compound possesses strong
antioxidant, astringent, antiviral and antibacterial properties
(9e11), reduces serum cholesterol and triglycerides, and sup-
presses lipogenesis (12). As a positive control, silymarin (SIL) is a
traditional herbal medicine, and previous pharmacological studies
demonstrated that SIL has a positive effect on the function of liver
cells (13), inﬂuencing the regenerative capacity of these cells via
antioxidant and protein-restoring activities. Carbon tetrachloride
(CCl4) induces hepatotoxicity via activated hepatic cytochrome
P450 concomitant with lipid peroxidation and eventually leads to
necrosis (14, 15). In this study, we studied the effect of TA on CCl4-
induced hepatic ﬁbrogenesis in vivo and on HSCs in vitro.
2. Material and methods
2.1. Animals
Fifty male Kunming mice (20 ± 2 g) were obtained from the
Laboratory Animal Center of Hebei Medical University. All animal
handing procedures were performed in accordance with the Na-
tional Institutes of Health Guide for Care and Use of Laboratory
Animals, and all experiments were endorsed by the Animal Ethics
and Use Committee of Hebei Science and Technical Bureau in China.
Afteroneweekof acclimation, themicewereweighedand randomly
divided into the control (CONT, saline, intraperitoneal (i.p.)), CCl4
(800ml/kg, 3 times perweek, i.p.), CCl4þ low-dose TA (L-TA, 25mg/
kg/day, intragastric (i.g.)), CCl4þ high-dose TA (H-TA, 50mg/kg/day,
i.g.) and CCl4 þ SIL (200 mg/kg/day, i.p., positive control) groups
(n¼10). TAandSILwere supplied bySigmaChemicals (St. Louis,MO,
USA). At the end of the 12th experimentalweek, all of themicewereFig. 1. A: Representative microscopic photographs were observed by H&E staining; B: Rep
Original magniﬁcation 400, the bars represent 50 mm. C: Masson's trichrome staining in ea
*P < 0.05, **P < 0.01 vs. CCl4 group. D: Chemical structure of TA.weighed and anesthetized with sodium pentobarbital (50 mg/kg).
The serum was separated for biochemical analysis, and the liver
samples were quickly excised and snap frozen in liquid nitrogen or
ﬁxed in a 4% paraformaldehyde solution.
2.2. HSC culture
HSCs were purchased from (Baili Biotechnology Co., Ltd,
Shanghai, China) and the purity is more than 98%. HSCs were
assessed via Trypan Blue exclusion to conﬁrm that the cell viability
was 95%. The HSCs were cultured according to a previous study
(16). To detect the cytotoxic effects of TA on HSCs, the experiments
were divided into six groups: the control (CONT), CCl4 (10 mM),
CCl4 þ low-dose TA (L-TA, 0.01 mM), CCl4 þmiddle-dose TA (M-TA,
0.1 mM), CCl4þ high-dose TA (H-TA, 1 mM) and CCl4þ SIL (10 mg/ml)
groups. Cells in the CCl4 group and CONT group were cultured in
DMEM medium, and the cells in the other groups were cultured
with TA or SIL. After 24 h, cells were exposed to CCl4 for 60 min.
Then, we removed the culture medium, washed the cells using
phosphate-buffered saline (PBS) and lysed the cells in 50 mmol/l
Na3VO4, 1 mmol/l phenylmethanesulfonyl ﬂuoride (PMSF) and
0.1 mmol/l aprotinin. The samples were centrifuged (15,000 g,
30 min, 4 C) to remove cell debris, and protein concentrations
were determined using the Bio-Rad protein assay (Bio-Rad Labo-
ratories, Inc., California, USA).
2.3. Biochemical analysis
The blood samples were centrifuged at 3000 g for 15 min, and
serum levels of aspartate aminotransferase (AST) and alanineresentative microscopic photographs were observed by Masson's trichrome staining.
ch group was calculated. Data are presented as mean ± SEM. ##P < 0.01 vs. CONT group.
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Analyzer (AU400; Olympus, Tokyo, Japan). The serum activities of
ET-1 and NO were assayed using ELISA kits (Jian Cheng Biological
Engineering Institute, Nanjing, China). The contents of MDA and the
activities of SOD, GSH-Px and CAT in hepatic tissues were estimated
according to the manuals provided with the assay kits (Jian Cheng
Biological Engineering Institute, Nanjing, China), and the pro-
cedures were described previously (17).2.4. Histopathology analysis
Hepatic tissue samples were stained with hematoxylin and
eosin (H&E) for histopathological studies or with Masson staining
reagents for hepatic collagen deposition, according to routine
staining steps that were described previously (18). We randomly
selected 50 ﬁelds at a 200magniﬁcation to determine the area of
ﬁbrosis (% positive area ¼ stained area/total area of the
tissue  100). IL-1b, TNF-a, TGF-b, c-fos, c-jun, MMP-9, TIMP-1 and
MMP-1 were analyzed via immunohistochemistry, which was
performed according to previously described manufacturer pro-
tocols (18).2.5. Western blotting analysis
A total of 20e100 mg of protein obtained from liver homogenate
fractions or HSCs lysates were used for analysis. Western blotting
was used to detect the expression of Bax, bcl-2, angiotensin II
receptor-1 (ATR-1), caspase-3, endothelial nitric oxide synthase
(eNOS), in liver tissues and expressions of TIMP-1, MMP-1 and
MMP-9 in HSCs. The Quantity One software (Bio-Rad, USA) was
used to scan the blots and quantify the bands.2.6. MTT assay for the analysis of HSC viability
The cell proliferation assay was performed using the 3-[4,5-
dimethylthiazol-2-ly]-2,5-diphenyltetrazolium bromide (MTT)
(SigmaeAldrich, St. Louis, MO, USA) colorimetric assay, which is
based on the reduction of the tetrazolium salt. The HSCs were
seeded in a 96-well plate (4 103 cells/well) and incubated with TA
and SIL for 24 h. Then, we added the MTT working solution (10 ml/
well, 5 mg/ml in PBS) and incubated the samples for 4 h at 37 C.
The medium were removed and the HSCs was dissolved using a
microplate reader. The cell viability was calculated as the per-
centage of MTT reduction, the absorption (A) of solubilized for-
mazan was measured at the wavelength of 490 nm by ELISA plate
reader and the absorbance of the CCl4 cells was set as 100%.2.7. Statistical analysis
Data are expressed as the mean ± SME. Statistically signiﬁcant
differences were identiﬁed using one-way analysis of variance
(ANOVA) and Tukey's multiple comparison tests. Differences were
considered statistically signiﬁcant at P < 0.05. The StatisticalTable 1
Effects of TA on liver weight and the activities of ALT and AST in serum of CCl4-intoxicat
Groups BW (g) LW (g) L
CONT 31.15 ± 1.28 1.21 ± 0.05 3
CCl4 30.95 ± 0.65 2.03 ± 0.11 6
L-TA 32.83 ± 1.72 1.81 ± 0.10 5
H-TA 32.59 ± 1.61 1.71 ± 0.09 5
SIL 32.35 ± 1.12 1.80 ± 0.08 5
Data are presented as mean ± SEM. ##P < 0.01 vs. CONT group. *P < 0.05, **P < 0.01 vs.Package for Social Sciences (SPSS, 16.0) software was used for the
analyses.3. Results
3.1. Amelioration of morphological changes by TA
3.1.1. Liver coefﬁcients and liver function changes in mice
The body weights and liver weights of the mice were measured,
and the relative liver weight was calculated as liver weight/body
weight  100. Our results demonstrated that the relative liver
weight increased signiﬁcantly in the CCl4 group compared to the
CONT group (P < 0.01, Table 1). The results also demonstrated that
the extent of liver injury was signiﬁcantly reduced in the L-TA and
H-TA groups (P < 0.01).
A biochemical analysis of the activities of ALT and AST in the
serum was performed to verify the role of TA in the protection of
livers treated with CCl4. As shown in Table 1, the activities of serum
ALT and AST in the CCl4 group (107.57 IU/L and 317.69 IU/L,
respectively) increased approximately 3-fold compared with the
activities observed in the CONT group (38.04 IU/L and 117.07 IU/L,
respectively). However, the activities of serum ALT and AST were
signiﬁcantly reduced by L-TA (71.95 IU/L and 156.27 IU/L, respec-
tively) and H-TA (68.01 IU/L and 141.75 IU/L, respectively, both
P < 0.01).3.1.2. Histological changes in mice
A histological examinationwas performed using H&E staining to
visualize the extent of the liver damage induced by CCl4. The liver
tissues in the control group revealed a normal architecture,
whereas the liver tissues in the CCl4 group showed the destruction
of the structure and the proliferation of ﬁbrous tissue (black tri-
angles). After treatment with TA, the liver tissues had regained a
normal structure and the degree of ﬁbrous tissue proliferation was
reduced (Fig. 1A).3.2. Attenuation of hepatic ﬁbrosis by TA
To observe the anti-ﬁbrosis effects of TA and explore the un-
derlying mechanisms, we ﬁrst measured the collagen distribution
in mice using Masson staining. We also detected the expression
levels of MMP-9, TIMP-1 and MMP-1 in mice using immunohisto-
chemistry and in HSCs using western blotting respectively.3.2.1. Masson staining
Masson staining is typically used to observe the localization of
collagen ﬁbers in liver tissues. As shown in Fig. 1B, the livers of mice
that were administered CCl4 showed typical characteristics of
ﬁbrosis (black triangles), and the ﬁbrotic tissue area increased
approximately 29-fold compared with the CONT group (Fig. 1C,
P < 0.01). After treatment with TA, the ﬁbrotic areas were signiﬁ-
cantly reduced in a dose-dependent manner.ed mice.
W/BW (g/g) ALT (UI/L) AST (UI/L)
.91 ± 0.11 38.04 ± 2.03 117.07 ± 6.53
.52 ± 0.41## 107.57 ± 5.62## 317.69 ± 14.13##
.52 ± 0.13* 71.95 ± 3.33** 156.27 ± 9.81**
.26 ± 0.13** 68.01 ± 3.54** 141.75 ± 8.39**
.56 ± 0.14* 92.91 ± 4.03* 183.91 ± 6.74**
CCl4 group.
Fig. 2. AeC: Representative microscopic photographs of MMP-9, MMP-1 and TIMP-1 in liver observed by immunohistochemistry. Original magniﬁcation 400, the bars represent
50 mm. The triangles indicate positive expression of MMP-9, MMP-1 and TIMP-1. 2DeF: the percentage positive area of MMP-9, MMP-1 and TIMP-1 in each group was calculated.
2GeH: expression levels of and the ratio of MMP-9 and TIMP-1/MMP-1 in HSCs observed by western blotting, the value of MMP-9 and ratio of TIMP-1/MMP-1 in each group was
calculated. Data are presented as mean ± SEM. ##P < 0.01 vs. CONT group. **P < 0.01 vs. CCl4 group.
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Table 2
Effects of TA on CCl4-intoxicated HSCs viability.
Groups A490 Cell viability (%)
CONT 0.26 ± 0.04 e
CCl4 0.48 ± 0.05 100
L-TA 0.31 ± 0.04 70.71 ± 10.32*
H-TA 0.29 ± 0.03 66.67 ± 9.89*
H-TA 0.23 ± 0.05 51.62 ± 10.44**
SIL 0.21 ± 0.04 43.01 ± 6.99**
The value of cell viability in CCl4 group was standardized as 100%. Data are pre-
sented as mean ± SEM. *P < 0.05, **P < 0.01 vs. CCl4 group.
X. Chu et al. / Journal of Pharmacological Sciences 130 (2016) 15e23 193.2.2. Immunohistochemistry analysis of MMP-9, TIMP-1 and
MMP-1 in mice
MMP-9 has the ability to denature and degrade collagens in
ECM. In the CCl4 group, the expression of MMP-9 and MMP-1 was
decreased, but the TIMP-1 was increased signiﬁcantly in compari-
son to that observed in the CONT group (P < 0.01). However, this
modulation effect was rescued by TA treatment in a dose-
dependent manner. Compared with the CCl4 group, in the L-TA
group and the H-TA group, the expression levels of MMP-9
increased by approximately 5.2-fold and 8.7-fold, respectively
(Fig. 2A, D), the expression levels of MMP-1 increased by approxi-
mately 2.2-fold and 4.7-fold, respectively (Fig. 2B, E), and the
expression levels of TIMP-1 decreased by approximately 3.0-fold
and 6.4-fold, respectively (Fig. 2C, F).
3.2.3. Western blotting analysis of MMP-9, TIMP-1 and MMP-1 in
HSCs
The TIMP-1/MMP-1 ratio and expression ofMMP-9were used to
express the degree of liver ﬁbrosis. The expression ofMMP-9 in CCl4
group was signiﬁcantly decreased compared with the CONT group
(P < 0.01). After pretreatment with TA (low-dose, middle dose andFig. 3. The activities of SOD, GSH-Px, CAT and the contents of MDA were measured in live
*P < 0.05, **P < 0.01 vs. CCl4 group.high-dose), the expression of MMP-9 was increased by 0.13-fold,
0.83-fold and 1.3-fold respectively (Fig. 2G). As shown in Fig. 2H,
CCl4 signiﬁcantly increased the TIMP-1/MMP-1 ratio by nearly 10-
fold in comparison to the CONT samples (P < 0.01). However, the
presence of TA (low-dose, middle dose and high-dose) signiﬁcantly
reduced the TIMP-1/MMP-1 ratio by 49.7%, 79.6% and 90.5%
respectively.
3.2.4. MTT analysis of HSC viability
The activation and proliferation of HSCs are closely related to the
pathogenesis and development of liver ﬁbrosis. The results showed
that CCl4 could increase HSC viability, promote cell proliferation
and eventually lead to ﬁbrosis. After treatment with TA, the cell
viability was reduced in a dose-dependent manner (Table 2).
3.3. Inhibition of oxidative stress by TA
CCl4 can trigger oxidative stress and lipid peroxidation and
cause the overproduction of free radicals, so we assessed the ac-
tivities of GSH-Px, SOD, and CAT and the contents of MDA in the
livers using biochemical analysis methods. The liver ﬁbrosis
induced by CCl4 signiﬁcantly reduced the liver GSH-Px, SOD and
CATactivities and increased the liverMDA content in comparison to
the CONT group (P < 0.01, Fig. 3). The results demonstrated that the
liver SOD, CATand GSH-Px activities were signiﬁcantly increased by
TA treatment (P < 0.01 for both the L-TA and H-TA groups). In
contrast, liver MDA levels were markedly decreased by treatment
with TA.
3.4. Prevention of inﬂammation by TA
The overexpression of proinﬂammatory cytokines may play a
role in accelerating the development of hepatic ﬁbrosis. Ther tissue homogenates. Data are presented as mean ± SEM. ##P < 0.01 vs. CONT group.
Fig. 4. Representative microscopic photographs of IL-1b and TNF-a in liver were observed by immunohistochemistry. Original magniﬁcation 400, the bars represent 50 mm. The
triangles indicate the positive expression. The percentage positive area of IL-1b and TNF-a in each group was calculated. Data are presented as mean ± SEM. ##P < 0.01 vs. CONT
group. **P < 0.01 vs. CCl4 group.
X. Chu et al. / Journal of Pharmacological Sciences 130 (2016) 15e2320immunohistochemical results showed that CCl4 could trigger in-
ﬂammatory reactions, inevitably leading to ﬁbrosis. The CCl4 group
exhibited elevated expression of the IL-1b and TNF-a proteins. In
contrast, after treatment by TA, the expression levels of the IL-1b
and TNF-a proteins were signiﬁcantly decreased compared with
the levels observed in the CCl4 group (Fig. 4, P < 0.01, respectively).
3.5. Effects of TA on endothelial function and on ATR-1
In this study, we detected changes in ET-1 and NO in the serum
using biochemical analysis methods and assessed the protein
expression levels of eNOS and ATR-1 in livers via western blotting.
The results showed that CCl4 may lead to endothelial dysfunction,
as indicated by increased ET-1 and ATR-1 levels and decreased NO
and eNOS levels compared with the control (all P < 0.01). After
treatment with TA, the function of the endothelial cells was
ameliorated, potentially contributing to the ability of TA to increase
NO and eNOS levels and decrease ET-1 and ATR-1 levels (Fig. 5).
3.6. Suppression of apoptosis by TA
Immunohistochemical analysis showed that the TGF-b, c-fos
and c-jun protein levels were rapidly up-regulated in the CCl4
group in comparison to the CONT group (P < 0.01, respectively).Compared to the CCl4 group, TA reduced the expression of TGF-b, c-
fos and c-jun by approximately 2.4-fold, 1.3-fold and 0.7-fold,
respectively, at the low dose and by 7.5-fold, 8.2-fold and 7.0-fold,
respectively, at the high dose (Fig. 6AeF). Similarly, western blot-
ting indicated that TA reduced the expression of caspase-3 and Bax/
bcl-2, which indicated that the anti-apoptosis abilities of the cells
increased (Fig. 6G, H).4. Discussion
Liver ﬁbrosis occurs due to a dynamic wound-healing response
to hepatocellular damage that is associated with a high risk of
signiﬁcant morbidity and mortality (19). Thus, investigations that
aim to identify effective methods for suppressing liver ﬁbrosis and
preventing the development of cirrhosis are urgently needed (20).
In this study, we used a model of chronic CCl4-induced liver injury
to study the potential molecular mechanisms that underlie the
anti-ﬁbrotic activities of TA. The results of this study clearly
demonstrate that certain biochemical changes occur in the liver
and serum of mice after the chronic administration of CCl4 for 12
weeks (7). Among these changes, the levels of AST and ALT
increased signiﬁcantly after the administration of CCl4. However, in
the TA treatment groups, these activities were signiﬁcantly
decreased, suggesting that TA prevents liver damage. This ﬁnding is
Fig. 5. A, B: Serum level of ET-1 and NO in the mice; 5C, D: Expression levels of ATR-1 and eNOS in hepatic tissues observed by western blotting. The data are presented as
mean ± SEM. ##P < 0.01 vs. CONT group. **P < 0.01 vs. CCl4 group.
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(Fig. 1A). Further investigations are currently underway to identify
the mechanism that underlies the protective effect of TA.
Liver ﬁbrogenesis is accompanied by increased deposition of
ECM in the perisinusoidal and periportal spaces (21). MMPs are
produced by activated HSCs and catalyze proteolysis. In contrast,
TIMPs regulate ECM homeostasis by binding to a particular MMP
and preventing its activity (22). The administration of CCl4 stimu-
lates HSCs to secrete TIMP-1 and decreases the activity of MMP-1
and MMP-9. In the TA-treated groups, the expression of TIMP-1
was signiﬁcantly decreased and the viability of HSCs was
reduced. Therefore, it is possible that TA regulates the ECM balance
via TIMP/MMP components and inhibits the activation of HSCs.
Oxidative stress is involved in the pathogenesis of hepatic injury
via the release of reactive oxygen species, and this type of stress
promotes the inﬂammatory response and damages the cellular
membrane, leading to the release of enzymes associated with
hepatotoxicity (23). We studied the hepatoprotective mechanisms
of TA using markers of oxidative stress, inﬂammation and liver
ﬁbrosis. In this study, TA decreased lipid peroxides in the liver tis-
sue, increased SOD, GSH-Px and CAT activity and decreased MDA
content in CCl4-treated mice (P < 0.01). Polyphenols, including TA,
have been considered to play a vital antioxidant role as dietary
antioxidants in the prevention of oxidative damage (24). The results
of this study revealed that the administration of TA signiﬁcantly
reduced CCl4-induced hepatic ﬁbrosis in mice due to the antioxi-
dant activities of polyphenols.
The release of proinﬂammatory cytokines TNF-a and IL-1b by
kuffer cells and stimulated multiplication of hepatic stellate cells is
one of the manifestations of liver ﬁbrosis (25). Inﬂammation con-
tributes to a number of pathological events and is further evident in
the current study based on the signiﬁcant increases in TNF-a and IL-1b levels that occurred in the CCl4-treated group in comparison to
either the control or the TA co-treated group. In the process of liver
ﬁbrosis, TNF-a is not only the mediator of inﬂammation but is also
involved in the mechanism of repairing parenchyma by activating
the proliferation of hepatocytes (26). Under normal conditions,
TNF-a exists as a type II transmembrane protein; however, this
factor is released in a soluble form by the metalloprotease TNF-a-
converting enzyme in response to cellular stress (27). Maintaining
TNF-a in a certain concentration range is important for cell pro-
tection; however, excessive amounts of this cytokinemay cause cell
injury. Increased expression of TNF-a could stimulate the release of
cytokines from macrophages and induce phagocyte oxidative
metabolism (28), thus leading to cascade synthesis of proin-
ﬂammatory cytokines (such as TNF-a, IL-6, IL-8) and then induced
ﬁbrotic changes (25). Co-treatment with TA can signiﬁcantly
decrease the levels of inﬂammatory factors. This activity suggests
that TA exerts a protective effect on liver function by inhibiting
inﬂammatory responses via the reduction of inﬂammatory factors.
Endothelial dysfunction, as described byPanza and Schiffrin (18),
is interpreted as a series of events that include vasoconstriction and
the pro-inﬂammatory response (29). These results indicated that
CCl4 could induce hepatic ﬁbrosis and apoptosis primarily by inter-
fering with endothelial function (increased hepatic ET-1 levels and
decreased serum levels of NO and eNOS). However, TA can increase
the level of NO, decrease hepatic levels of ET-1 and improve the
hepatic microcirculation. Previous studies suggested that Ang-II
induced ﬁbrosis in association with its ability to promote the pro-
liferation of ﬁbroblasts and the synthesis of ECM (30). This stimu-
latory effect is mediated by ATR-1 (31). Treatment with TA resulted
in a signiﬁcant dose-dependent reduction of ATR-1 expression
(Fig. 5C), and this result demonstrated that the TA-mediated down-
regulation of ATR-1 expression is a hepatic protection pathway.
Fig. 6. AeC: Representative microscopic photographs of TGF-b, c-fos and c-jun in hepatic observed by immunohistochemistry. Original magniﬁcation 400, the bars represent
50 mm. The triangles indicate the positive expression. DeF: The percentage positive area of TGF-b, c-fos and c-jun in each group was calculated. G, H: Expression levels of caspase-3,
Bax and bcl-2 in hepatic tissues observed by western blotting, the value of TIMP-1/MMP-1 in each group was calculated. Data are presented as mean ± SEM. ##P < 0.01 vs. CONT
group. **P < 0.01 vs. CCl4 group.
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X. Chu et al. / Journal of Pharmacological Sciences 130 (2016) 15e23 23Apoptosis and necrosis contribute to the process of liver ﬁbrosis
(32). A previous study indicated that CCl4 can induce hepatocellular
damage, which is characterized by necrotic cell death (33). To date,
TGF-b, c-fos, c-jun, caspase-3, Bax and bcl-2 have been identiﬁed as
markers of apoptosis (Fig. 6). All of our results showed that TA could
inhibit the occurrence and progression of apoptosis by regulating
the expression of the above-mentioned apoptosis factors.
In summary, the results of this study showed that TA could
effectively repair the injury and improve the pathological changes
that occur during CCl4-induced liver ﬁbrosis. These ﬁndings indi-
cate a new pharmacological use for TA that may be attributed at
least in part to the inhibition of lipid peroxidation, the suppression
of inﬂammatory reactions, the induction of apoptosis in hepato-
cytes and the inhibition of HSC activation.
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